Search results
Results From The WOW.Com Content Network
Post-treatment monitoring Osteopontin (OPN) is a promising tool for monitoring praziquantel efficacy and post-treatment fibrosis regression as (OPN) expression is modulated by S. mansoni egg antigens and its levels correlate with the severity of schistosomiasis fibrosis and portal hypertension in mice and humans. Praziquantel pharmacotherapy ...
A schistosomicide is a drug used to combat schistosomiasis. [1] List. Examples listed in MeSH include: [2] amoscanate; arteether; artemether; chloroxylenol; hycanthone;
Schistosomiasis life cycle. Source: CDC [citation needed] A Schistosomiasis vaccine is a vaccine against Schistosomiasis (also known as bilharzia, bilharziosis or snail fever), a parasitic disease caused by several species of fluke of the genus Schistosoma. No effective vaccine for the disease exists yet.
Schistosomiasis is caused by parasitic worms, picked up in infested waters, which drill through people's skin and lay eggs in their bodies. Parasitic worms may hold key to cutting spread of HIV ...
Schistosoma japonicum is an important parasite and one of the major infectious agents of schistosomiasis.This parasite has a very wide host range, infecting at least 31 species of wild mammals, including nine carnivores, 16 rodents, one primate (human), two insectivores and three artiodactyls and therefore it can be considered a true zoonosis.
The prevention of schistosomiasis involves avoiding contact with contaminated freshwater sources, such as swimming, wading, or bathing in stagnant water, especially in endemic areas. Proper sanitation and hygiene practices, such as washing hands and clothes properly, can reduce the risk of infection.
The Schistosomiasis Control Initiative had developed an approach which would cost 50 US cents per person per year, and was piloted in Burundi and Rwanda in 2007 with a $9 million investment from the Legatum Foundation, along with support from various other government donors, philanthropists and pharmaceutical companies, over a four-year period.
Thus, this receptor is essential in preventing the progression of schistosomiasis from the acute to the chronic (and deadly) stage of disease. Synthetic IL-13Rα2 given to mice has resulted in significant decreases in granuloma size, implicating IL-13Rα2 as an important target in schistosomiasis. [55]